Notícias

RapAdmin

A new theoretical framework, the Brain-Body Energy Conservation model, suggests that age-related immune decline is not simply a random failure of bodily systems but an adaptive, energy-saving response to the rising metabolic costs of chronic inflammation. As the body expends energy to manage accumulating cellular damage, it reallocates resources away from maintaining the adaptive immune system, specifically the naive T cell repertoire. While this strategy promotes short-term survival, it leaves older adults significantly more vulnerable to novel pathogens like the virus responsible for COVID-19.

The aging process is characterized by two distinct but concurrent immune phenomena: inflammaging, the steady rise of chronic, sterile systemic inflammation, and immunosenescence, the progressive decline of adaptive immunity. For decades, researchers have viewed these processes as parallel dysfunctions. However, recent data from two massive human cohorts, the US Health and Retirement Study and the UK Biobank, strongly suggests a direct, resource-driven link between the two.

The Brain-Body Energy Conservation model views the human body as a closed economic system with a finite metabolic budget. In later life, total and basal energy expenditures actually decrease. Yet, the accumulation of senescent cells creates a highly energetically demanding environment due to their continuous senescence-associated secretory profile signaling. To fund the high metabolic cost of managing this chronic cellular damage, the body must divest energy from other systems. The primary victim of this biological budget cut is the adaptive immune system.

Maintaining a robust naive T cell repertoire through the thymus is an expensive investment in future protection. When resources are tight, the body prioritizes immediate survival over future defense. This results in thymus involution and a sharp drop in naive T cells. The data reveals that markers of inflammaging, specifically Tumor Necrosis Factor Receptor 1 (TNFR1), directly mediate the decline in naive T cells. As TNFR1 levels rise, naive T cell counts fall.

Furthermore, this energy conservation response is governed by specific signaling molecules. The metabolic stress marker GDF-15 and the anti-inflammatory cytokine IL-10 both increase with age and chronic disease. These molecules act as metabolic brakes, suppressing the immune response to conserve energy. The real-world consequence of this trade-off is stark. Individuals with higher levels of these exact markers prior to the pandemic experienced significantly higher rates of hospitalization and death from COVID-19. The body’s attempt to survive the chronic stress of aging left it defenseless against a novel acute threat.

Actionable Insights

For individuals actively managing their biological age, the primary takeaway is that suppressing systemic inflammation is a prerequisite for maintaining adaptive immune capacity.

First, mitigating inflammaging markers, particularly TNFR1, is critical. The data shows that having diabetes increases the odds of severe COVID-19 outcomes by 106 percent, while hypertension or cardiovascular disease increases the odds by 53 percent. These cardiometabolic diseases drive the inflammatory cascade that ultimately shuts down naive T cell production.

Second, the reliance on GDF-15 as a key mediator of immune suppression highlights the importance of managing metabolic stress. Each standard deviation increase in GDF-15 was associated with significantly reduced naive T cell counts and higher vulnerability to novel infections.

Finally, interventions known to reduce the senescence-associated secretory profile, such as senolytics or mTOR inhibitors like rapamycin, likely improve immune function not by stimulating the immune system directly, but by reducing the energetic burden of inflammaging. By lowering the metabolic cost of chronic inflammation, these interventions may allow the body to reallocate resources back toward maintaining a robust naive T cell repertoire.

Context/Source

RapAdmin

Early Bird Pricing until October 14th! Only $299 (vs. $600).

The Longevity Summit’s sixth annual event is coming this December. ! It will take place over two days at the scenic Buck Institute for Research on Aging in Novato, California.

This immersive conference includes ample time to converse over shared meals and after hours wine and hors d’oeuvres. We gather the entire longevity ecosystem to tackle the aging problem: longevity entrepreneurs, existing pharma and biotech companies, investors, researchers, and government organizations. Developing aging interventions may represent the largest value creation journey in human history, and it’s going to require a coordinated industry.

Developing aging therapies requires both new science and new business models. The Longevity Summit will explore the key topics that leaders within the industry need to know in order to turn longevity research into prescribable medicine. Join us as we explore the following topics:

  • Drug Discovery
  • Regulatory Approval
  • Clocks, Biomarkers, and Age Measurement
  • Longevity Medicine
  • Data Collection
  • Longevity Clinical Trials
  • Funding Longevity Biotech
  • Replacement Strategies
  • Regenerative Medicine
  • Gene Editing & CRISPR
  • The Root Causes of Aging
  • Public Perception

Register now: The Longevity Global Summit 2026

RapAdmin

Japanese researchers screened sixteen common food compounds for the ability to stop cultured mouse muscle cells from filling up with fat, and pterostilbene, a naturally methylated cousin of resveratrol found in blueberries and grapes, came out on top. It cut lipid accumulation by roughly a third at 10 micromolar and by more than half in the strongest induction model. The mechanism is the interesting part. Pterostilbene did not shut down fat synthesis, and it did not stop fat from entering the cell. Instead it raised the protein level of PPAR-delta, the nuclear receptor that switches on fat burning genes, by about sevenfold, and it did so without binding to the receptor’s ligand pocket at all. Rather than acting as a drug-like agonist, pterostilbene appears to protect PPAR-delta from being tagged with ubiquitin and shredded by the proteasome. Knocking down PPAR-delta erased roughly 84 percent of the effect. Everything here is cell culture, sample sizes are three per group, and no animal was dosed.

For twenty years the stilbene story in longevity has been the resveratrol story, and the resveratrol story has been a disappointment. The compound is poorly absorbed, cleared within minutes, and its headline mechanism, SIRT1 activation, has been argued over since 2005. Pterostilbene has drifted along in its shadow as the more bioavailable relative, absorbed roughly four times better in rats, but has mostly been assumed to do the same things by the same routes. This paper suggests that assumption is wrong, at least in muscle.

The team at Shinshu University started with a blunt screen. They forced mouse C2C12 muscle cells to accumulate fat using a chemical cocktail, then threw sixteen food-derived compounds at them and stained for lipid. Caffeine did nothing. Curcumin did nothing. Sulforaphane did nothing. Three compounds worked, and pterostilbene worked best.

Then they did the experiment that makes the paper worth reading. They tested pterostilbene’s structural relatives side by side at the same concentration. Resveratrol itself did not reduce lipid. Plain stilbene did not. Neither single-methoxy variant did. Only the compound carrying methoxy groups at both the 3 and 5 positions had the effect. Whatever pterostilbene is doing in muscle, resveratrol does not do it, and half a pterostilbene molecule does not do it either.

The mechanism turned out to run through PPAR-delta, a nuclear receptor that acts as the master switch for fat oxidation in muscle. Pterostilbene raised PPAR-delta protein about sevenfold and turned on a coordinated set of fat burning genes: the carnitine shuttle enzymes that carry fatty acids into mitochondria, the enzymes that chop them up once inside, and PDK4, which pushes the cell away from burning sugar and toward burning fat. Silencing PPAR-delta removed most of the benefit.

The surprise came in the last figure. The researchers ran a binding assay comparing pterostilbene against GW501516, the synthetic PPAR-delta agonist that bodybuilders once bought as Cardarine and that regulators eventually flagged for carcinogenicity in animals. GW501516 lit up the receptor’s ligand pocket nineteenfold. Pterostilbene produced a 1.1-fold signal, which is to say nothing at all. It never touches the pocket.

What it appears to do instead is interfere with the receptor’s disposal. PPAR-delta that is not bound to a ligand gets tagged with ubiquitin and fed to the proteasome within hours. Pterostilbene reduced that tagging, so the receptor survives longer and accumulates. It is a difference between pressing the accelerator and removing the brake on the accelerator’s supply chain, and it may matter for safety, since the toxicity concerns around synthetic PPAR-delta agonists come from forcing the receptor into sustained maximal activation.

There is also something the paper did not chase. Cells treated with pterostilbene roughly doubled their fusion index, meaning they merged into muscle fibers more readily. That was reported and left alone.

Notably, the cells did not build more mitochondria. Mitochondrial DNA copy number and the biogenesis machinery were unchanged. This is not an exercise mimetic that expands capacity. It is a signal that tells existing mitochondria to work on a different fuel.

Actionable Insights

It is cell culture, and the working concentration of 10 micromolar equals about 2,563 nanograms per milliliter of unconjugated pterostilbene in the dish. Whether a human taking a capsule reaches anything close to that inside a muscle fiber is unknown. Pterostilbene is heavily sulfated after absorption, so most of what circulates is not the active molecule.

What the effect sizes do tell you is the shape of the claim if it holds. At 10 micromolar the fat reduction was about 34 percent, and in the free-fatty-acid model about 33 percent, which removed roughly 64 percent of the fat the cells had just taken on. Fat burning genes rose 55 to 170 percent. Glycerol release, a marker that stored fat is being broken apart, rose about 40 percent. Large changes statistically, but drawn from three samples per group, which inflates apparent precision considerably.

Three things are worth carrying forward. First, if you take pterostilbene, you are not taking a more bioavailable resveratrol, because resveratrol did nothing in this system. Second, the target here is intramuscular fat, a real and underrated aging problem distinct from body fat. If using pterostilbene you need to watch how much it raises your LDL lipid levels.

Context and Source

  • Paywalled Paper: Pterostilbene suppresses intracellular lipid accumulation in C2C12 myocytes via PPARδ stabilization
  • Institutions: Division of Food Science and Biotechnology, Graduate School of Science and Technology, Shinshu University, Nagano, Japan; Department of Food Science, Ishikawa Prefectural University, Ishikawa, Japan; Department of Agricultural and Life Sciences, Faculty of Agriculture, Shinshu University, Nagano, Japan
  • Country: Japan
  • Journal: Food Bioscience (Elsevier), Volume 83, 2026.
  • Impact evaluation: The impact score of this journal is 5.9 (most recent Journal Citation Reports release; the 2023 JIF was 4.8, five-year JIF 6.1), evaluated against a typical high-end range of 0-60+ for top general science, therefore this is a Medium impact journal.

RapAdmin

Rapamycin significantly reduces the susceptibility to age-related atrial fibrillation by reversing pathological metabolic shifts in the heart. Researchers demonstrated that rapamycin administration in an accelerated aging mouse model preserved heart structure and electrical conductivity. This protective effect is driven by the suppression of hypoxia-inducible factor 1-alpha, which prevents the heart from switching to an inefficient, glycolysis-dependent metabolic state.

Atrial fibrillation represents the most common clinical arrhythmia and is tightly linked to advancing age. Aging hearts undergo structural deterioration and electrical instability that create an environment ripe for arrhythmias. Underlying these physical changes is a fundamental metabolic crisis. Healthy hearts rely on the efficient burning of fatty acids in the mitochondria. In contrast, aged and failing hearts experience mitochondrial damage and shift their energy production toward anaerobic glycolysis, a phenomenon resembling the Warburg effect seen in cancer cells.

Researchers at Xi’an Jiaotong University investigated whether rapamycin could halt this arrhythmogenic decline. Using a mouse model where accelerated aging was induced via continuous D-galactose injections, the team evaluated the electrical and structural health of the atria. The chemically aged mice developed severe metabolic dysfunction, systemic insulin resistance, and highly inducible atrial fibrillation. Following a twelve-week dietary regimen of rapamycin, the treated mice exhibited profound improvements. The rapamycin intervention restored insulin sensitivity, prevented atrial hypertrophy, reduced tissue fibrosis, and maintained normal electrical conduction velocities.

The primary mechanism centers on hypoxia-inducible factor 1-alpha (HIF-1α). HIF-1α is a transcription factor that drives the pathological shift toward glycolysis and impairs fatty acid oxidation. The aging mice showed marked elevations in HIF-1α activity and subsequent lactic acid accumulation in the heart tissue. Rapamycin treatment successfully suppressed HIF-1α expression, thereby preserving mitochondrial integrity and normal fatty acid metabolism.

The study revealed an unexpected molecular interaction. Rapamycin is universally known to operate by inhibiting the mechanistic target of rapamycin (mTOR) pathway. While the canonical mTOR pathway does regulate HIF-1α, the researchers utilized molecular docking and isothermal titration calorimetry to show that rapamycin also binds directly to the HIF-1α/ARNT protein complex. This direct binding disrupts the dimerization of the complex and inhibits its transcriptional activity independently of mTOR. Pharmacological experiments forcing the reactivation of mTOR signaling confirmed that rapamycin still suppressed HIF-1α nuclear accumulation. This identifies a dual-action mechanism where rapamycin acts as a direct molecular inhibitor of HIF-1α.

Actionable Insights

For individuals focused on healthspan extension, this research positions rapamycin as a systemic metabolic modifier rather than just a cellular growth inhibitor. The data indicates that maintaining metabolic flexibility in cardiac tissue is a primary defense against age-related arrhythmias.

The intervention demonstrated massive real-world efficacy in preserving cardiac output. In the accelerated aging model, untreated mice saw their left ventricular ejection fraction degrade to a median of 46.68%. The rapamycin cohort maintained an ejection fraction of 61.17%, generating an absolute improvement of 14.49%. Statistical extraction yields a Cohen’s d of 2.23, representing a remarkably large standardized effect size.

Regarding arrhythmia prevention, the absolute risk reduction was dramatic. The control aging mice experienced a 69.44% frequency of induced atrial fibrillation. Rapamycin treatment suppressed this frequency to 11.56%, translating to an 83.4% relative risk reduction. The absolute duration of fibrillations dropped from 6.6 seconds to under 2 seconds. These calculations strongly suggest that rapamycin protocols could offer substantial protection against physical and electrical cardiac decline by forcibly maintaining youthful mitochondrial substrate utilization.

Context/Source

Leitura Relacionada:

RapAdmin

Researchers at Jilin University tracked 44,025 UK Biobank participants for roughly 14 years and found that a single stress-response protein measured in plasma at the start, GDF15, predicted who would later develop nine separate brain disorders. People in the top quarter of GDF15 had about five times the rate of Alzheimer’s disease and about three times the rate of stroke compared with the bottom quarter, after adjustment for age, sex, lifestyle and cardiometabolic history. Inflammatory and lipid markers explained only a small slice of the association, mostly through neutrophil count and HDL cholesterol.

Growth differentiation factor 15 is what cells release when things are going badly. Damaged mitochondria trigger it. Metabolic stress triggers it. Inflammation, hypoxia and tissue injury all trigger it. It is one of the most reliable blood markers of biological strain that anyone has found, and it climbs steadily with age in almost everyone.

A team led by Changgui Kou and Wei Bai asked a simple question of the UK Biobank: if you measure this protein once, in middle age, how much does it tell you about what happens to a person’s brain over the next decade and a half?

The answer is a lot. Among 44,025 people who had no diagnosed brain disorder when their blood was drawn, 6,939 went on to develop one. Sorting participants by their baseline GDF15 produced a steep gradient. Those in the top quarter developed all-cause dementia at roughly five times the rate of the bottom quarter and Alzheimer’s disease at roughly five times the rate, with stroke at three times and epilepsy at twice. Even conditions with no obvious link to metabolic stress, such as sleep disorders and depression, showed a clear signal. Every one of the nine outcomes tested moved in the same direction, and the pattern held across seven different sensitivity analyses.

That consistency is the strength of the paper. It is also, in a sense, its problem. A marker that predicts dementia, stroke, Parkinson’s, epilepsy, depression, anxiety and insomnia all at once is probably not telling you something specific about any of them. It is telling you something general about the person.

The authors then did the thing that separates a careful paper from a promotional one. They used Mendelian randomisation, which exploits the random assortment of genes at conception to approximate a natural experiment, to ask whether GDF15 causes any of this. For eight of the nine outcomes, the answer came back null. Genetically higher GDF15 did not predict dementia, stroke, Parkinson’s, depression or sleep problems. For anxiety it ran backwards, with genetically higher GDF15 associated with lower risk, a result the authors themselves treat as suspect.

So GDF15 is a witness, not a culprit. It sits downstream of whatever is actually damaging the brain, faithfully reporting the accumulated burden.

That is still useful. Most of what clinical medicine currently offers for brain aging risk arrives too late, after cognitive symptoms are already visible. A protein that separates high from low risk fourteen years in advance, from a single tube of blood, has obvious value for enrolling the right people into prevention trials and for deciding who deserves aggressive vascular risk management.

What it does not offer is a target. Lowering GDF15 pharmacologically, which several companies are attempting for cachexia and obesity, would on this evidence do nothing for the brain. It would be like smashing the fuel gauge to fix an empty tank.

The more useful question the paper leaves open is what drives GDF15 up in the first place. Declining kidney function and chronic mitochondrial stress are the leading candidates. Neither was measured.

Actionable Insights

There is no supplement or drug here to take. GDF15 is a symptom of underlying strain, and the genetic analysis argues that pushing it down would not help your brain. What the paper offers is a calibration of how much risk a marker of general physiological stress carries.

Over 14 years, comparing the top quarter of GDF15 with the bottom quarter after adjusting for age, sex, smoking, BMI and cardiometabolic history, the absolute differences work out to roughly 3.3 extra dementia cases per 100 people, 5.5 extra strokes per 100, and 10.6 extra cases of any brain disorder per 100. You would need about 30 people to move from the high group to the low group to prevent one dementia case, if the relationship were causal. It is not, so treat that as a ceiling on what any GDF15-lowering intervention could deliver.

Two practical points survive. The strongest signals were vascular and neurodegenerative rather than psychiatric, which reinforces that blood pressure, lipids and glucose remain the highest-yield modifiable targets. And the two leading mediators, neutrophil count and HDL cholesterol, already sit on a standard blood panel.

Context and Source

  • Paywalled Paper: Peripheral GDF15 as an early biomarker for brain disorders: A large prospective cohort study
  • Institution: Department of Epidemiology and Biostatistics, School of Public Health, Jilin University, Changchun, Jilin Province
  • Country: China
  • Journal: Progress in Neuro-Psychopharmacology and Biological Psychiatry
  • Impact evaluation: The impact score of this journal is 4.2 (Journal Impact Factor, most recent reported; the 2022 figure was 5.6 and has declined since), evaluated against a typical high-end range of 0 to 60+ for top general science journals, therefore this is a Medium impact journal.

Leitura Relacionada:

RapAdmin

Researchers profiled 172 routine clinical measurements in 104,208 Chinese adults aged 18 to 98 and used them to build separate biological aging clocks for men and women. The clocks are not interchangeable: a model trained on one sex loses substantial accuracy when applied to the other, which the authors treat as formal evidence that male and female physiology age along genuinely different paths. Mapping each measurement across the lifespan revealed two distinct midlife inflection windows, a male metabolic dysregulation phase at ages 35 to 45 and a female endocrine-metabolic remodeling phase at ages 55 to 65, after which the sexes physiologically converge in late life. The most novel observation is that conventional tumour markers such as carcinoembryonic antigen (CEA) and human epithelial protein 4 (HE4) accumulate with age in a cancer-free population, correlate with accelerated biological aging in a dose-dependent fashion, and, when applied to human aortic endothelial cells in culture, are sufficient to induce a senescent phenotype. Circulating LDL, triglycerides, glucose and uric acid did the same. A high-fat-diet mouse model with dietary reversal indicated that the resulting liver senescence burden is partly modifiable.

A team working across three Chinese hospitals has done something the aging field has discussed for years but rarely delivered: they built a biological age calculator out of the blood and urine tests a doctor already orders, then showed that men and women need entirely different calculators.

The dataset is the reason to pay attention. Researchers under the X-Age Project pulled 172 routine clinical measurements from 104,208 people aged 18 to 98 attending standard health checkups in Beijing, Quzhou and Nanchang. No methylation arrays, no proteomics, no expensive assays. Cholesterol, blood pressure, liver enzymes, urine chemistry, hormones, blood counts, and 17 tumour markers.

The first result is a mapping problem solved. When the team trained an age predictor on men and applied it to women, accuracy fell off sharply, and the same happened in reverse. That failure is the finding. It means the physiological signature of a 55-year-old man and a 55-year-old woman is not the same object measured with noise. They are different objects.

Tracking the measurements across the lifespan produced two distinct midlife crunch points. In men, a cluster of metabolic measures including body mass index, cholesterol and triglycerides peaks between 35 and 45, then falls away. In women, a later peak arrives between 55 and 65, dominated by the collapse of estradiol and progesterone and the surge in follicle-stimulating hormone that defines menopause, tangled together with the same metabolic markers. Two clocks, two alarm times.

Then, in old age, the sexes converge. Blood pressure and uric acid in women climb steeply through midlife until they approximate male levels. Hemoglobin and hematocrit in men fall until they approach the steadier female baseline. By the ninth decade much of the physiological difference between the sexes has closed.

The most unexpected result concerns tumour markers. These are proteins oncologists track in cancer patients: carcinoembryonic antigen, human epithelial protein 4, CA 19-9 and others. In a population screened as cancer free, these proteins rose steadily with age, and the more of them a person had elevated, the older their body tested relative to their birthday. Staining tissue from young and old donors confirmed the pattern: these proteins accumulate in aging ovary, pancreas, lung, liver and intestine.

The team then went past correlation. They took human aortic endothelial cells, the lining of arteries, and exposed them to those tumour marker proteins. The cells turned senescent. They also exposed the cells to LDL, triglycerides, glucose and uric acid at concentrations chosen to reflect real blood, and got a consistent result: senescence markers up, nuclear envelope proteins down, migration impaired, inflammatory signalling switched on.

Two things partly reversed it. Metformin, added alongside high glucose in the dish, pushed several senescence markers back toward normal. And mice fattened on a 60 percent fat diet for 15 weeks, then returned to regular chow for 9 weeks, showed liver senescence markers fall substantially, though not all the way back to control levels.

The claim the authors land on is that metabolic burden is not merely a correlate of aging but a driver of it, and that the driving is reversible.

Actionable Insights

Four things follow from this paper.

First, sex matters when interpreting a biological age result. A clock built on one sex misreads the other. If you use a biological-age service (which we don’t recommend because they are generally not validated at the individual level), ask whether the underlying model was sex-stratified.

Second, systolic blood pressure separates fast agers from slow agers more sharply than anything else measured here. Comparing the fastest-aging 5 percent against the slowest-aging 5 percent in Beijing, systolic pressure differed by roughly 22 mmHg in men and 38 mmHg in women. Expressed as Cohen’s d, that is approximately 1.2 and 1.9. A d of 1.0 means the average person in one group sits above about 84 percent of the other, so this is a wide separation. The caveat is that blood pressure is one of the clock’s own inputs, so part of that gap is built in.

Third, tumour markers carry aging information even after cancer is excluded, but the individual signal is weak. Two or more elevated markers shifted median biological age by only about 2 to 4 years against a spread of roughly 20 years, a Cohen’s d near 0.4. One elevated CEA is not a verdict on your aging rate.

Fourth, the metabolic damage looks partly reversible. Mice removed from a high-fat diet cut liver senescent cell burden by roughly 60 percent in 9 weeks.

Context and Source

  • Paywalled Paper: Sex-specific aging clocks from a large-scale human phenome reveal distinct aging transitions and circulating signatures
  • Institutions: Beijing Institute of Genomics and China National Center for Bioinformation, Chinese Academy of Sciences; Quzhou People’s Hospital / Quzhou Affiliated Hospital of Wenzhou Medical University; Xuanwu Hospital Capital Medical University; First Affiliated Hospital of Nanchang University; West China Hospital of Sichuan University; Institute of Zoology, Chinese Academy of Sciences; Beijing Anzhen Hospital.
  • Country: China (multicentre: Beijing, Quzhou, Nanchang; tissue samples from Chengdu)
  • Journal: Nature Aging (Springer Nature). published online 25 August 2026.
  • Impact evaluation: The impact score of this journal is 25.0 (2025 two-year Journal Impact Factor; 5-year JIF 26.0, SJR 9.500, SNIP 3.978), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a High impact journal.

RapAdmin

Researchers at the University of Colorado Anschutz Medical Campus took muscle biopsies from nineteen healthy men, nine sedentary and ten meeting the standard 150 minutes per week activity guideline, and profiled their skeletal muscle with high resolution respirometry, metabolomics, stable isotope tracing, and a graded cycling test. Sedentary muscle showed reductions of 28 to 36 percent across the electron transport chain, 51 percent lower CPT1 activity, lower cardiolipin, and a 49 percent reduction in MPC1, the mitochondrial pyruvate carrier. Glucose uptake machinery (GLUT4) and cytosolic lactate enzymes (LDHA, LDHB) were unchanged.

Physical inactivity is linked to more than five million deaths a year, and the usual explanation is close to circular: sedentary people are unfit, and unfit people get sick. A team at the University of Colorado Anschutz Medical Campus went looking for something more specific, and what they report sits inside the mitochondria of ordinary muscle.

They took vastus lateralis biopsies from nineteen healthy men, nine who did no structured exercise and ten who met the standard 150 minutes a week guideline. Nobody was diabetic. Nobody had cardiovascular disease. On paper, everyone was healthy. The tissue went through high resolution respirometry, mass spectrometry, and isotope tracing, and the men then rode a bike to exhaustion.

Sedentary muscle was worse at nearly everything, which is not the surprise. The pattern of the deficit is. The machinery that pulls glucose out of the blood was untouched. GLUT4, the glucose transporter, was present in identical amounts in both groups, as were the two enzymes that interconvert pyruvate and lactate. The failure was one step further in. MPC1, half of the gate that carries pyruvate across the inner mitochondrial membrane, was down by roughly half in the sedentary men. It was the largest single difference in the study.

The picture is a traffic problem. Sugar still enters the muscle cell normally. It is still broken down to pyruvate normally. But the door into the mitochondrion, where that pyruvate would be burned, appears narrower. Pyruvate backs up, gets shunted to lactate, and spills into the blood. On the bike, the sedentary men reached five millimoles of lactate at a workload where the active men were still below two.

The same story repeats on the fat side. CPT1, which loads long chain fatty acids into mitochondria, ran at about half the activity in sedentary muscle. Cardiolipin, the lipid that holds the respiratory chain in working formation, was also lower. Both fuels are being kept out of the furnace.

The authors are careful, and the caution matters. They cannot say whether the shrunken pyruvate gate causes the decline or simply reflects having fewer mitochondria per gram of muscle. They never counted mitochondria, which is the measurement that would settle it. And because this compares two groups of people at a single moment, it cannot establish whether inactivity produced the phenotype or whether people with better mitochondria are more inclined to exercise in the first place.

What the work does offer is a practical hook. Blood lactate and fat oxidation during submaximal cycling tracked the biopsy findings closely enough that the authors propose them as a non invasive readout of mitochondrial condition. Lactate above 2.5 millimoles combined with fat oxidation below 0.4 grams per minute at 50 to 60 percent of maximal oxygen uptake is their candidate signature of subclinical mitochondrial trouble.

That is a testable proposition rather than a validated test. It also rests, for now, on nineteen men.

Actionable Insights

Three things here are worth acting on.

First, the size of the gap. Statisticians use Cohen’s d, which measures the distance between two group averages in units of the natural spread within a group. A d of 0.2 is small, 0.8 is large. This study reported 1.2 to 2.2. Translated into something intuitive: pick one sedentary man and one active man at random, and the active man has more mitochondrial pyruvate carrier protein about 93 percent of the time, and higher aerobic fitness about 94 percent of the time. These are not subtle differences.

Second, the dose associated with them was modest. The active group were not athletes. They did 150 minutes a week of aerobic exercise, the standard public health minimum, sustained for at least six months. Their aerobic fitness averaged around 46 mL/kg/min against 28 in the sedentary group.

Third, blood lactate during moderate exercise is a cheap proxy for what a biopsy showed. At 125 watts, sedentary men averaged 5.1 mM against 1.5 mM in active men, a 3.4 fold difference.

Implications:

The implication of these fitness differences in these two groups of men is significant. The Cohort is of healthy men, mean age 41.9 years. The US male period life table (SSA, 2023 data) gives a cumulative 10-year mortality of 4.2 percent for a man aged 42. Splitting that population average around a relative risk of 2:

  • Active group: roughly 3 percent chance of death in the decade
  • Sedentary group: roughly 6 percent

The relative difference is large. The absolute difference is about 3 percentage points, or roughly 1 excess death per 33 sedentary men over ten years. Ninety-four percent of the sedentary group will be alive at 52.

The important point is this; between age 42 and 52 the two groups are building a divergence, not paying for one. The mortality bill for this decade’s physiology arrives in the 60s and 70s.

Context and Source

RapAdmin

A Wellcome Sanger Institute team sequenced 810 tissue samples from 172 donors aged 0 to 93 and measured, for the first time in one consistent experiment, how fast DNA errors accumulate in 53 different human cell types. The headline result is that mutations pile up in a straight line across the entire lifespan in almost every tissue, including cells that never divide, but the speed of that line varies more than 18-fold between organs. Sperm precursors accrue about 3.5 mutations per year, neurons about 17 to 20, colon lining cells about 52, liver cells about 63, and sun-exposed skin several hundred.

For thirty years the study of somatic mutation has been hampered by a technical embarrassment: DNA sequencers make more errors than cells do. A method called duplex sequencing solved that by reading both strands of every DNA molecule separately and accepting a mutation only when both strands agree. The Sanger group has now applied it at scale, and the result is the closest thing biology has to a speedometer reading for every major cell type in the human body.

The big idea is that ageing at the genome level is not one process running at one speed. It is dozens of processes running at different speeds in different rooms of the same house, and we can now read every dial.

Three findings stand out. The first is that accumulation is linear. Mutations do not snowball late in life; they arrive at a steady rate from birth to death in most tissues. The team tested curved and exponential models explicitly and the straight line won. That is what you would see if the rate of DNA damage, the efficiency of repair and the accuracy of copying all held roughly constant across eighty years. It is a quietly deflating result for anyone hoping a late-life intervention could slam the brakes on a runaway process, because there is no runaway to stop.

The second is that cell division is not the main engine. Neurons and heart muscle cells, which essentially stop dividing in early life, still accumulate around 17 to 37 mutations a year, comparable to many tissues that renew constantly. Whatever damages DNA does not need the cell to be copying its genome to do it. That points instead at slow chemical decay of the DNA molecule itself, running in the background of every cell whether or not it is doing anything.

The third, and the most consequential for public health, is that tobacco smoke mutates organs far from the lung. The study finds smoking signatures in liver cells, heart muscle, kidney tubules and bladder lining. Smoke chemicals enter the bloodstream and mutate tissue systemically. Cardiac muscle cells, which barely divide and cannot be replaced, carry the mark, and the affected heart samples came from the left side, which receives blood directly from the lung.

There is also a genuine puzzle at the centre of the dataset. The single largest contributor to the body’s total mutation burden is a pattern called SBS5, present in every cell type in every person, found in every mammal studied, and with no known cause. It runs at ten times the normal rate in liver cells and is almost switched off in sperm precursors, and nobody can say why. The authors name identifying its mechanism as the top priority coming out of the work, a striking admission for a field this mature.

Finally, the result the field will argue about. If mutations cause cancer, tissues with higher mutation rates should be more cancer-prone. Outside skin, they largely are not. Something other than raw mutation count, most likely how many cells a tissue has, how much they can still divide, and when in life the mutations land, is setting cancer risk.

Actionable Insights

Do not smoke, and if you have smoked, understand the scope. This paper shows tobacco mutating the liver, heart, kidney and bladder, not just the lung. Bladder lining cells vary between people by an amount equal to roughly 33 years of average mutation accumulation, and the paper attributes most of that spread to a smoking-linked pattern. In liver cells the equivalent figure is about 25 years, in heart muscle about 31 years. For comparison, brain and naive immune cells vary by only 4 to 5 years between individuals. Smoking is not a modest contributor to this variance; it is the dominant one the study could identify.

Protect skin from ultraviolet light. Skin epidermis has the highest mutation rate of any cell type measured, several hundred per year against a body-wide median near 25, and its person-to-person variation is driven almost entirely by ultraviolet signatures.

Alcohol leaves a distinct mutational signature in mouth and oesophageal lining in some individuals.

Context and Source

  • Open Access Paper: A comprehensive atlas of somatic mutation rates and mutational signatures in normal human cells
  • Lead institution: Somatic Genomics Programme, Wellcome Sanger Institute, Cambridge, United Kingdom
  • Contributing countries: United Kingdom, Netherlands, Japan, United States
  • Journal: bioRxiv preprint, posted 29 August 2026
  • Journal Impact Evaluation This is a preprint server deposit, not a journal article, so the requested metric cannot be applied as specified. Stated in the required format for completeness:

RapAdmin

**A Dutch multiomics study of 47 muscle biopsies reports that roughly 56 percent of the gene expression changes that distinguish old muscle from young muscle are simply absent in older adults who have trained consistently for years. The preventable fraction is dominated by mitochondrial energy metabolism, including electron transport chain subunits, mitochondrial ribosomal proteins, and NAD+ pathway metabolites. The fraction that persists regardless of training clusters instead around synaptic transmission and WNT signalling, with no dominant pathway. A second finding is that trained older adults do not merely age more slowly at rest, they also respond to an acute exercise bout in a pattern that resembles young adults. **

For decades the standard picture of muscle aging has been a slow, uniform slide. Mitochondria falter, energy metabolism drifts, strength goes. A Dutch team has now taken that picture apart and found that it is really two pictures stacked on top of each other, and only one of them responds to exercise.

Georges Janssens, Riekelt Houtkooper and colleagues at Amsterdam UMC and Maastricht University recruited 47 people and took muscle biopsies from the thigh. Eleven were in their twenties. The other 36 were over 65 and were sorted by how much they actually moved: 16 long-term exercisers averaging around 14,000 steps a day plus at least three training sessions a week, 15 people living an ordinary active life at roughly 9,600 steps, and five with measurable physical impairment. Everyone then rode a stationary bike for an hour at half their personal maximum and gave a second biopsy immediately afterwards. Every sample was run through three molecular readouts at once: more than 24,000 gene transcripts, 135 metabolites and 1,383 individual lipid species.

The headline number is the split. Comparing the young group with the ordinary older group produced a long list of genes that change with age. When the same comparison was run against the trained older group, roughly 56 percent of those changes were not there. Their muscle had not aged less in every respect. It had failed to age in a specific respect.

What falls into the preventable half is telling. It is dominated by the machinery of energy production: electron transport chain components such as NDUFS1 and COX5A, and a cluster of mitochondrial ribosomal proteins that build the respiratory apparatus itself. The metabolite data pointed the same way, with NAD+ pathway compounds among the ten most age-altered molecules, alongside triglyceride buildup inside the muscle fibre.

The unavoidable half looks nothing like it. Those genes cluster around synaptic transmission and WNT signalling, meaning the wiring between nerve and muscle and the developmental programmes that maintain tissue structure. No single pathway dominates, which the authors read as drift rather than a targetable process.

The second finding may matter more in practice. Aging did not just blunt the response to that hour on the bike, it distorted it. Ordinary older adults depleted and accumulated metabolites at four to six times the rate of the young, and accumulated four times as many altered lipid species. The trained older adults responded in a pattern closer to the young, and their inflammatory signalling genes, including IL6 and IL1B, fired harder than in their sedentary peers, not softer. Fitness bought a stronger stress response, not a quieter one.

The caveat is structural and the authors state it. Nobody was randomised. These are people who chose to train for decades, in a country where cycling is ordinary and where the sedentary comparison group still walks close to 10,000 steps a day. The trained group was also about three years younger and leaner. What the study establishes is that half of the muscle aging signature is compatible with being absent, and where the other half lives.

Actionable Insights

Maintaining regular, structured endurance training preserves cellular energy production into late life. Casual daily walking is insufficient to safeguard mitochondrial capacity; older participants logging 9,600 steps per day still experienced widespread bioenergetic decline, whereas individuals completing at least three 1-hour structured exercise sessions weekly maintained youthful muscle profiles.

The magnitude of this protective benefit is substantial. Exercise prevented 55.9% of normal age-related gene upregulations and 57.1% of age-related gene downregulations. For mitochondrial respiratory complex I and complex V gene expression, training kept median transcript counts within approximately 5% to 10% of young levels, contrasting with a 30% to 50% decrease seen in untrained older adults. Standardized effect sizes across respiration markers and clinical stamina indices between trained and untrained individuals regularly exceeded 1.2 standard deviations (Cohen’s d).

Practical guidance highlights the necessity of reaching genuine cardiovascular exertion rather than merely accumulating low-intensity steps. In addition, practitioners must be cautious with non-specific, long-term anti-inflammatory interventions: the transient inflammatory and stress response provoked by exercise is an indispensable signal that drives tissue remodeling and cellular resilience in aging muscle.

Context/Source

RapAdmin

An economics-led team applied unsupervised machine learning to fifty years of Global Burden of Disease data and re-sorted 304 diseases not by their biology but by the age at which they strike. Four natural groups emerged: infant, early-adult, later-adult and aging-related. The aging-related group is now the largest single source of health loss on the planet, it is the largest expected lifetime burden facing a newborn in every income bracket, and it behaves differently from the other three in two measurable ways. Its diseases kill and disable the same people at the same time, and the payoff from reducing them grows as you reduce them.

For half a century global health has run on a simple storyline. Poor countries lose children to infection, rich countries lose adults to heart disease and cancer, and development moves a nation from one state to the other. Abdel Omran named it the epidemiological transition in 1971, and it has shaped where money goes ever since. A new analysis in Nature Aging argues the storyline is wrong in an important way.

The research team, led by economists Julian Ashwin and Andrew Scott alongside global health figures David Bloom and Peter Piot, took Global Burden of Disease data covering 304 diseases and injuries across 204 countries from 1990 to 2023 and did something unusual. Instead of sorting conditions into the standard bins of communicable and non-communicable, they let an algorithm sort them by when in life they strike. The method, K-means++ clustering, was given a single input: how much health loss each disease causes per person at each age.

Four groups fell out. Infant diseases, including measles, malaria and diarrhoeal illness. Early-adult diseases, including HIV, road injuries and maternal conditions. Later-adult diseases, including most cancers and much of mental illness. And a fourth group whose burden climbs with age and then stays high: ischaemic heart disease, chronic obstructive pulmonary disease, type 2 diabetes, chronic kidney disease and dementia.

That fourth cluster is now the largest single category of disease burden in the world. Its share has grown from roughly a quarter in 1990 to a little over two-fifths today, while the infant share has fallen from just above half to below thirty per cent. The classification holds steady across three decades.

Two properties make the aging cluster distinctive. First, the diseases that kill are largely the same ones that disable, so there is no tradeoff between adding years and adding healthy years. Second, and this is the paper’s central claim, the returns to fighting these diseases rise as progress is made. Because aging-related conditions accumulate in the same bodies, preventing one raises the value of preventing the next. Halve their prevalence and the gain is about 2.2 times what a quarter reduction buys by 2050, rising to 3.2 times by 2100. Remove them entirely, a hypothetical the authors use as a ceiling rather than a plan, and global life expectancy would rise by 17.4 years, past ninety.

Insights

First, the ceiling. Removing every aging-related disease worldwide would add 17.4 years to average life expectancy, roughly a 24 per cent gain on a base near 73 years. Removing all infant, early-adult and later-adult disease combined would add 5.3 years. The aging cluster is worth about 3.3 times all other life stages put together. That is the size of the prize, and it is a theoretical maximum, not an achievable target.

Second, the compounding. Halving the prevalence of aging-related disease buys about 2.2 times what a quarter reduction buys, not the 2.0 times a straight line would predict. That 10 per cent premium is the measurable value of stacking prevention across multiple systems rather than one condition at a time. By 2100 the same comparison is 3.2 versus 2.0, a 60 per cent premium.

Third, no tradeoff. For aging-related diseases the correlation between how much a disease kills and how much it disables is 0.59. For early-adult diseases it is 0.26. In plain terms, the strongest lever on lifespan and the strongest lever on healthspan are the same lever.

Context and Source

  • Paper: Aging rises, yet the double burden of illness remains. Published 2 September 2026.
  • Institutions: Maastricht University, Netherlands; Harvard T.H. Chan School of Public Health and NBER, USA; Ellison Institute of Technology, Oxford, UK; London School of Hygiene and Tropical Medicine, UK; London Business School, UK; Centre for Economic Policy Research, France. Access status:
  • Journal: Nature Aging (Springer Nature).
  • Impact: The impact score of this journal is 25.0, evaluated against a typical high-end range of 0-60+ for top general science, therefore this is a High impact journal.